The isoflavonoid genistein, the aglycone of the heteroside genistin, possesses preventive effect on coronary heart disease and osteoporosis, antioxidant, anthelmintic, antineoplastic and anti-inflammatory properties. Much research has been undertaken regarding the action of genistein on cancerpreventing/treating effects, especially on breast and prostate cancer. The aim of this study was to analyze the effect of this compound in vivo by observing tumor size, metastasis potential and melanization in a mouse model of murine melanoma, employing the B164A5 melanoma cell line and C57BL/6J mice. Genistein decreased the tumor volume and weight by approximately 30%. Non-invasive measurements for both melanin and erythema showed that genistein reduced the quantity of melanin and the degree of erythema in direct proportion to the number of days of treatment. HE analysis diagnosed malignant melanoma in both groups, but no metastasis was recorded in the treated group compared with the liver metastasis in the untreated group after a period of 15 days of experiment at a dose of 15 mg/kg body weight of genistein. Genistein showed beneficial effects regarding tumor size, metastasis potential and melanization in a B16 mouse model of murine melanoma.
The isoflavonoid genistein(4', 5, 7-trihydroxyisoflavone) represents the major active compound from soybean (Glycine max Family Fabaceae) [1] . Previous studies have demonstrated that genistein possesses many biological functions: a preventive agent of coronary heart disease and osteoporosis, antioxidant, anthelmintic, antineoplastic and anti-inflammatory activities [2] [3] [4] [5] .Concerning its anticancer mechanism, until now it is reported that genistein is a potent in vitro inhibitor of protein tyrosine kinase (PTK) activity, especially that of the epidermal growth factor receptor (EGF-R) [1, 6] and also inhibits topoisomerase II, phosphatidylinositol turnover, ABC transporters, and other proteins such as ribosomal S6 kinase, nuclear factor Y/CAAT, TGFB, CFTR, aromatase, and type I 17β-hydroxysteroid reductase [7] [8] [9] [10] . It is reported that genistein induces apoptosis, inhibits cell proliferation, modulates cell cycle progression, inhibits angiogenesis, suppresses lymphocyte activation and proliferation, stabilizes mast cells, presents mild anti-inflammatory properties and inhibits the production of reactive oxygen species [1, 7, [11] [12] [13] . Furthermore, genistein modulates the actions mediated by estrogen receptors (ER), being considered a phytoestrogenic compound [14, 15] . Latest data about genistein as an antitumor agent are focused on the cancer-preventing/treating effects, especially on breast and prostate cancer [16] [17] [18] . A series of studies showed an inhibitory action of genistein on breast and prostate cancer cell lines [19, 20] . Approaches have been made in the study of melanoma employing the B16 mouse melanoma cell line [21] , but the studies on this cell line are limited. Information still needs to be obtained about the action of genistein on malignant melanoma, especially in vivo.
This study focused on supplementing the deficient information regarding the activity of genistein on melanoma development by analyzing the effect of genistein on tumor size, metastasis potential and melanization in a mouse model of murine melanoma employing the B164A5 melanoma cell line.
B164A5 cells were prepared and injected using standard protocols. Tumors became visible on day 9 after inoculation in both treated and untreated groups. From the moment of appearance until the end of the experiment (day 17) tumor growth was measured and tumor volume calculated. Results are shown in Figure 1 . In a period of 8 days the tumor volume increased from the day of appearance from 523.2±0.2 mm 3 to 2,445.5±0.3 mm 3 in group B, compared with mice in group C, treated with 15 mg/kg body weight genistein, where data show an increased volume of the tumor from 467.0±0.05 mm 3 to 1,599.1±0.15 mm 3 . A positive correlation was obtained in terms of reduction in tumor volume between the treated mice and the time of treatment (number of days). At the end of the study, the volume of the tumor had decreased by 34.6% in the case of treated mice compared with untreated ones.
Melanin and erythema values (both arbitrary units, as described in the experimental section) were measured at baseline (day 0) and every two days after that until day 17 of the experiment. Results are presented in Figures 2 and 3 .
During the 17 days of the experiment, melanin showed increased values in groups B and C compared with the control group, A. Until day 9 from inoculation no significant differences were found between groups B and C; the values attributed to melanin amount were overlapped, increased corresponding to augmentation of the number of the days and higher compared with the control. On day 9, the day that tumors became visible, the amount of melanin was 748.0±0.1 in the case of group B, very close to that of group C, 757±0.1, but both values were higher than that of the control, group A,669.0±0.2. This linear increase in the values attributed to melanin in the range: group A<group C<group B was kept until the last day of experiment, when the recorded values were 680.0±0.3 for group A; 780±0.3 for group C and 820±0.3 for group B. Genistein reduced the quantity of melanin starting from day 13 by 4.7%, reaching a difference of 4.9% on day 17.
Mexameter measurements also allowed the observation of changes in erythema degree. The values for erythema for mice in group B were more than double in the last day of the experiment compared with control: 89.7±0.03 group A versus 192.7±0.4group B, which indicates a skin trauma, a lesion. In the case of group C, the values for the arbitrary units representing the intensity of erythema were lower than in the case of group B: 164.3±0.04, thus the results present the positive role of genistein in the recovery of skin lesion type murine malignant melanoma. Again there was a linear increase inthe values attributed to erythema in the range: group A<group C<group B; this was maintained until the end of the experiment.
On day 17 after inoculation, mice were sacrificed by cervical dislocation and macroscopic examination of the main visceral organs was made. No significant differences between the treated and untreated groups were observed. Slightly stained and enlarged liver was noticed in mice in group B and slightly enlarged liver was noticed in some cases in mice in group C.
One can observe the presence of subcutaneous tumors in both inoculated groups, but with difference in the size of tumors ( Figure  4 ). In the case of group C, tumors were smaller thanin the case of group B . An average weight of tumors in group C was 1.55±0.35 g/mouse. A higher average value was observed in group B 2.35±0.04 g/mouse. Growth of solid tumors implanted into female C57BL/6J mice was inhibited by 34% when genistein was injected i. p. at daily doses of 15 mg/kg body weight.
After macroscopic examination, histological analyses were performed. Groups B and C were diagnosed with melanoma ( Figures 5a and 5b ). Regarding the main visceral organs, HE analysis showed a metastatic process in the liver of mice in group B (untreated group), with no metastatic process in mice in group C (treated group) (Figures 6a and 6b ).
In order to study experimental cancer therapies very well established models of transplantable murine melanomas have been developed. The B16 mouse model for melanoma has been widely used because it has the advantage of being metastatic and syngeneic with the C57BL/6J background [22] . Application of melanin measurement is justified because of the nature of the pathology and can be helpful for monitoring treatment impact. After the inoculation of B164A5, cells tumors became visible on day 9 after inoculation in both treated and untreated groups. Nathanson et al. worked on other B16 sublines (F1, F10, BL6) injected in the left foot pad and concluded that black tumor became macroscopically visible in the second week following inoculation [23] . After 15 days of treatment the volume of the tumor decreased by 34.6%. Genistein was also tested for this purpose, using a recognized chemical carcinogenic agent, 7,12-dimethylbenz[α]anthracene (DMBA), and the conclusion was that genistein reduced the incidence of skin tumors by about 20% [2] . 7,12-Dimethylbenz[α]anthracene is currently used as an agent for experimentally melanoma [24] .
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Skin pigmentation is directly proportional to the amount of melanin [25] , and melanin measurement by Mexameter MX18 is a noninvasive method currently used in skin research [26, 27] . Genistein reduced the quantity of melanin by 4.9% until the end of the experiment. It was proved that in vitro genistein inhibited melanin synthesis in cultured melan-a cells in a dose dependent manner and tyrosinase activity was decreased, but not inhibited [28, 29] .
Mexameter measurements were used to detect changes in the degree of erythema, which occurs with any skin lesion [30] . In the present study, a linear increase was observed for the values attributed to erythema in the range: group A<group C<group B. Other groups observed that genistein reduces erythema obtained in other conditions than the ones presented in this study: PUVA and UVB induced photo damage [31, 32] .
On day 17 after inoculation, mice were sacrificed. Tumors were observed in both groups, but with differences regarding their size. Tumors arose subcutaneously after s. c. inoculation of B164A5 cells in C57BL/6J mice [33, 34] . Growth of solid tumors implanted into female C57BL/6J mice was inhibited by 34% when genistein was administrated. Yan et al. investigated the action of genistein on another B16 subline, B16BL6, and observed that genistein suppressed the growth and induced differentiated phenotypes in B16-BL6 melanoma cells [35] .
HE analysis confirmed the presence of malignant melanoma in both treated and untreated groups. In the steps of evolution melanoma is characterized by a radial and vertical growth phase [36, 37] . The larger the primary tumor grows, the more likely it is that it will be able to acquire traits that lead to a metastasis phenotype [38, 39] . Regarding the main visceral organs, HE analysis showed a metastatic process on the liver of mice in group B (untreated group), with no metastatic process in mice in group C (treated group). Record et al. also underlined a decrease in tumor size in mice implanted with another similar melanoma cell line B16F0, which is a low metastatic potential cell line. Guo et al. worked with B16F10, a high metastatic potential cell line, on B6C3F1 mice and concluded that exposure to this compound significantly increased host resistance to B16F10 tumor, as reflected by a decrease in the number of lung tumor nodules. In another study, Donghua et al. investigated the effect of dietary supplementation with isoflavones on pulmonary metastasis of B16BL6 murine melanoma cells in C57BL/6 mice and concluded that dietary supplementation with isoflavones reduced experimental metastasis of melanoma cells in mice and also inhibited the growth of metastatic tumors that developed in the lungs [21, 40, 41] .
The present study provides evidence that a period of 15 days of treatment with genistein at a daily dose of 15 mg/kg body weight genistein/C57BL/6J mouse implanted s. c. with B164A5 melanoma cells reduces the growth of B16 tumors, the melanin amount, the degree of erythema and suppress liver metastases.
Experimental
General: Genistein was acquired from Extrasynthèse (France, purity >95%). Mouse adherent melanoma cell line B164A5 was purchased from ECACC (European Collection of Cell Cultures, Salisbury, UK). Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% non-essential amino acids and 1% penicillin-streptomycin in a humidified atmosphere containing 5% CO 2 at 37°C. All cell culture media and supplements were obtained from Life Technologies (Paisley, Scotland, UK). In order to prepare the cells for injection, cells were trypsinized, counted by trypan blue, washed with PBS, resuspended at a concentration of 1*10 5 cells/0.1 mL in saline solution and injected immediately, as described below.
Animal studies: Animal studies were conducted on 7-8 week old C57BL/6J female mice with an average weight of 20-25g. Mice were purchased from Charles River (Sulzfeld,Germany). The work protocol followed all NIAH rules: animals were maintained during the experiment in standard conditions: 12 h light-dark cycle, food and water ad libitum, temperature 24°C, humidity above 55%. The experiment was conducted according to the rules of the Ethical Committee of the "Victor Babeş" University of Medicine and Pharmacy of Timişoara, Romania. The number of mice included in the study was 30 and the mice were divided equally into 3 groups as follows: group A -blank, group B -mice inoculated with B164A5 cells, and group C -mice inoculated with B164A5 cells and treated with genistein dissolved in 0.9% saline solution by sonication.
On day 0, mice in groups B and C received subcutaneous (s. c.) injections into the hair-depilated lateral abdomen of 0.1 mL of 1*10 5 cells/mouse. To study the effect of genistein on tumor implants, mice from group C were injected from day 2 until day 16 of the experiment intra peritoneally (i.p.) with daily doses of 15 mg/kg body weight genistein,sonicated into suspension in 0.9% saline prior to injection. Group B was inoculated with the same volume of solvent. Mice were inspected daily for the development of tumors or other changes. Tumor growth was measured in mm, daily, using calipers, and tumor volume was estimated by the formula: length x width 2 /2.On day 17 from inoculation, after the last measurements were made, mice were sacrificed by cervical dislocation. Tumors were collected, measured, weighted, and afterwards histological analyses were performed. Results are presented as mean ± S. D (standard deviation).
Non-invasive skin measurements:
The measurements on the mice skin were carried out with a Multiprobe Adapter System (MPA5) from Courage-Khazaka-Mexameter® MX 18, Germany .The range of values is 0-1000, with a higher value representing more melanin or erythema. Measurement was made for 4 parts of the skin and mean and standard deviation were calculated. Melanin and erythema values were measured at baseline (day 0) and every 2 days after that until day 17. The measurement area was 5 mm in diameter. Afterwards, mice were sacrificed. Skin and main visceral organs were collected. Histological analyses were performed.
Histology: For the histological analyses, tissue samples (skin) were fixed in 10% formalin solution and were embedded in paraffin and 4 µm sections were cut. Finally, after deparaffinization, the samples were stained with hematoxylin-eosin and microscopically analyzed.
Statistic: Paired Student's t tests or One-way Anova followed by Bonferroni's post-tests were used to determine the statistical difference between various experimental and control groups;*, ** and *** indicate p<0.05, p<0.01 and p<0.001
